Join the NIHR online Q&A: severe neuromuscular diseases in children

Published:

Updated:

On Wednesday 12th July 2023, 7pm to 8pm the National Institute for Health and Care Research, which supports delivery of research in the NHS, public health and social care and Muscular Dystrophy UK, the UK charity for individuals and families living with muscle-wasting conditions are hosting a webinar where you can ask leading experts about the latest research into severe neuromuscular disorders in children

The webinar will include University of Oxford’s Dr Sithara Ramdas and Prof Laurent Servais who will answer your questions in an ‘ask the expert’ event. They will invite questions about Duchenne muscular dystrophy, congenital muscular dystrophy, congenital myopathy, inherited neuropathy, limb girdle muscular dystrophy and spinal muscular atrophy.

You can find out more information, and find the link to sign up in advance here. (You must sign up in advance if you wish to attend).

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more